CCL20 is a potential therapeutic target associated with immune infiltration in breast cancer

Zhai, Hongyan; Zhang, Na; Mo, Dan; Qin, Tingting

doi:10.1177/03000605231171762

Cited by 2 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other chemokines play a role in monocyte/macrophage recruitment. In particular, CCL20 expression on neutrophils and macrophages was also significantly correlated with immune cell infiltration in breast cancer, including monocytes, neutrophils, TAMs, Th1 cells, regulatory T cells, and exhausted T cells [ 31 ] ( Table 2 ). Intriguingly, C-X-C motif chemokine 1 (CXCL1) has been identified to be increased in aggressive bladder cancer and correlated with TAM recruitment [ 32 ], a role also played by CXCL12 [ 33 ] ( Table 2 ).…”

Section: Recruitment Of Monocytes/macrophages Into Tumorsmentioning

confidence: 99%

New Strategies for Macrophage Re-Education in Cancer: An Update

Lampiasi

2024

IJMS

View full text Add to dashboard Cite

The association between cancer and inflammation is well established. Chronic inflammation represents a fundamental step in the development and progression of some types of cancer. Tumors are composed of a heterogeneous population of infiltrating cells including macrophages, fibroblasts, lymphocytes, granulocytes, and mast cells, which respond to signals from the microenvironment and, in turn, produce cytokines, chemokines, transcription factors, receptors, and miRNAs. Recent data demonstrate that, in addition to classical (M1) and alternative (M2) macrophage subtypes, there are many intermediate subtypes that potentially play different roles in response to environmental stimuli. Tumors are infiltrated by macrophages called TAMs that mainly display an M2-like phenotype and tumor growth-permissive activities. There is a bidirectional interaction between tumor cells and tumor-infiltrating cells that determines macrophage polarization and ultimately tumor progression or regression. These complex interactions are still unclear but understanding them is fundamental for the development of new therapeutic strategies. Re-educating tumor-permissive macrophages into anti-tumor macrophages is a new focus of research. This review aims to analyze the most recent articles investigating the interplay between tumors, tumor-infiltrating cells, and TAMs, and the strategies for re-educating tumor-permissive macrophages.

show abstract

Section: Recruitment Of Monocytes/macrophages Into Tumorsmentioning

confidence: 99%

New Strategies for Macrophage Re-Education in Cancer: An Update

Lampiasi

2024

IJMS

View full text Add to dashboard Cite

show abstract

Identification of CCL20 as a Prognostic Predictor for Severe Fever With Thrombocytopenia Syndrome Based on Plasma Proteomics

Zhang,

Li,

Liu

et al. 2024

The Journal of Infectious Diseases

View full text Add to dashboard Cite

Background Severe fever with thrombocytopenia syndrome (SFTS), a lethal tick-borne hemorrhagic fever, prompted our investigation into prognostic predictors and potential drug targets using plasma Olink Proteomics. Methods Employing the Olink assay, we analyzed 184 plasma proteins in 30 survivors and 8 non-survivors of SFTS. Validation was performed in a cohort of 154 SFTS patients using enzyme-linked immunosorbent assay. We utilized the Drug Gene Interaction database to identify protein-drug interactions. Results Non-survivors exhibited 110 differentially expressed proteins (DEPs) compared to survivors, with functional enrichment in the cell chemotaxis-related pathway. Thirteen DEPs, including C-C motif chemokine 20 (CCL20), calcitonin gene-related peptide alpha and Pleiotrophin, were associated with multiple organ dysfunction syndrome. CCL20 emerged as the top predictor of death, demonstrating an area under the curve of 1 (P = .0004) and 0.9033 (P < .0001) in the discovery and validation cohort, respectively. Patients with CCL20 levels exceeding 45.74 pg/mL exhibited a fatality rate of 45.65%, while no deaths occurred in those with lower CCL20 levels. Furthermore, we identified 202 FDA-approved drugs targeting 37 death-related plasma proteins. Conclusions Distinct plasma proteomic profiles characterize SFTS patients with different outcomes, with CCL20 emerging as a novel, sensitive, accurate, and specific biomarker for predicting SFTS prognosis.

show abstract

CCL20 is a potential therapeutic target associated with immune infiltration in breast cancer

Cited by 2 publications

References 40 publications

New Strategies for Macrophage Re-Education in Cancer: An Update

New Strategies for Macrophage Re-Education in Cancer: An Update

Identification of CCL20 as a Prognostic Predictor for Severe Fever With Thrombocytopenia Syndrome Based on Plasma Proteomics

Contact Info

Product

Resources

About